Laborie Medical Technologies, a Portsmouth, NH-based diagnostic and therapeutic medical technology company, acquired Urotronic, a Plymouth, MN-based private medical device company that developed drug-coated balloon technology used in interventional urology to treat urethral strictures and benign prostatic hyperplasia (BPH) or enlarged prostate conditions.
The amount of the deal was not disclosed.
Led by President and CEO David Perry, Urotronic is a medical device company currently conducting clinical trials to support global commercialization of their products. The Optilume® drug-coated balloon technology provides a minimally invasive treatment option for men suffering from urinary tract conditions like urethral strictures and benign prostatic hyperplasia (BPH). Optilume combines mechanical dilation with the delivery of paclitaxel to treat lower urinary tract symptoms (LUTS) secondary to urological stricture or BPH. The products have been approved by the U.S. Food and Drug Administration (FDA) and received the CE mark.
Led by Michael Frazzette, President and CEO, Laborie is a global medical technology company focused on Urology, Urogynecology, Gastroenterology, Obstetrics, Gynecology & Neonatal Health. It manufactures and delivers diagnostic and therapeutic products that help clinicians and hospitals preserve and restore patient dignity. The company supports its products with a clinical education and information program for clinicians and hospitals. Laborie is a portfolio company of Patricia Industries.
FinSMEs
30/10/2023